Quadrature Capital Ltd Makes New $19.60 Million Investment in Johnson & Johnson $JNJ

Quadrature Capital Ltd acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 105,744 shares of the company’s stock, valued at approximately $19,604,000.

Several other institutional investors have also modified their holdings of JNJ. SOA Wealth Advisors LLC. increased its holdings in Johnson & Johnson by 0.7% in the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after buying an additional 53 shares during the last quarter. Ethos Financial Group LLC lifted its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after buying an additional 53 shares during the last quarter. Pinnacle Holdings LLC boosted its position in shares of Johnson & Johnson by 0.5% during the 3rd quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock worth $2,079,000 after acquiring an additional 54 shares in the last quarter. Bouchey Financial Group Ltd increased its holdings in shares of Johnson & Johnson by 0.8% in the 3rd quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock valued at $1,344,000 after acquiring an additional 54 shares during the last quarter. Finally, Heritage Oak Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 3.5% in the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after acquiring an additional 55 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $242.43 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The stock has a 50 day moving average of $231.22 and a two-hundred day moving average of $205.79. The stock has a market cap of $584.24 billion, a P/E ratio of 21.94, a P/E/G ratio of 2.40 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the TECNIS PureSee intraocular lens for U.S. cataract patients — a commercial win for J&J’s Vision franchise that could drive incremental device sales and strengthen the company’s near-term revenue mix. Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens
• Positive Sentiment: Citigroup raised its price target to $274 and placed a Buy rating — a bullish analyst call that signals meaningful upside versus the current share level and may attract buyers. Benzinga
• Positive Sentiment: BofA increased its price target to $253 (from $227) citing pipeline growth while keeping a Neutral rating — the higher target and raised revenue assumptions reflect improving visibility on key drugs and support medium-term upside. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: JNJ requested an EU label expansion for multiple myeloma drug Tecvayli based on phase III MajesTEC-9 data — approval would broaden indicated use and market opportunity in oncology. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Analyst commentary (Zacks) highlights J&J among names with strong business momentum despite macro headwinds — supportive narrative for investor confidence. The Zacks Analyst Blog: JPMorgan, Johnson & Johnson, Applied Materials and Value Line
• Neutral Sentiment: Coverage/narrative updates show modest fair‑value adjustments (e.g., fair value moved slightly to ~$237) as analysts rework individual drug assumptions — incremental but not game‑changing. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
• Neutral Sentiment: Barclays reaffirmed a Hold rating — keeps a portion of sell‑side sentiment cautious despite positive pipeline headlines. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: J&J appears on lists of “safe” dividend aristocrats — supportive for income investors but unlikely to trigger large near‑term moves. Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on JNJ shares. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Bank of America restated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $250.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Morgan Stanley set a $262.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $235.91.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.